ANI Pharmaceuticals (ANIP) FY2017 results: revenue $177 million, up 37.5% on the year
ANI Pharmaceuticals Inc. (ANIP) reported revenue of $177 million for fiscal 2017, the year ended 31 December 2017, up 37.5% on the year before. Net income was -$1 million, and diluted earnings per share $-0.09. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2018.
Revenue
$177 million
+37.5% on the year
FY2010FY2017
Operating margin
16.0%
15.6% a year earlier
FY2010FY2017
Net income
-$1 million
FY2010FY2017
Diluted EPS
-$0.09
FY2010FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
177
129
76.3
+37.5%
Cost of revenue
79.0
48.8
12.7
+62.0%
Gross profit
97.8
79.8
63.6
+22.5%
Gross margin
55.3%
62.1%
83.4%
Research and development
9.1
2.9
2.9
+212.1%
Selling, general and administrative
31.6
27.8
21.2
+13.5%
Operating income
28.3
20.1
32.7
+41.1%
Operating margin
16.0%
15.6%
42.8%
Interest expense
11.3
11.3
11.1
+0.3%
Pre-tax income
16.3
8.7
21.7
+88.4%
Income tax
17.4
4.7
6.4
+267.3%
Effective tax rate
106.6%
54.7%
29.3%
Net income
-1.1
3.9
15.4
Net margin
-0.6%
3.1%
20.1%
Diluted EPS
-$0.09
$0.34
$1.32
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
39.4
27.5
17.3
+43.5%
Capital expenditure
10.4
4.6
2.2
+127.1%
Free cash flow
29.1
22.9
15.1
+26.8%
Free cash flow margin
16.4%
17.8%
19.8%
Cash from investing
-108
-149
-32.7
Cash from financing
72.4
-0.7
1.1
Depreciation and amortisation
27.9
22.3
6.9
+25.0%
Share-based compensation
6.1
6.1
3.9
+0.4%
Buybacks
0.0
2.5
0.0
Diluted shares, weighted
12m
12m
12m
-0.2%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
175
170
160
+3.0%
Debt
202
121
113
+67.0%
Other liabilities
35.9
32.6
11.8
+10.1%
Total liabilities and equity
412
323
285
+27.7%
Fixed assets
20.4
11.0
7.1
+85.5%
Goodwill
1.8
1.8
1.8
0.0%
Intangible assets
230
176
66.4
+30.7%
Cash and equivalents
31.1
27.4
155
+13.8%
Receivables
58.8
45.9
21.9
+28.1%
Inventory
37.7
26.2
13.4
+44.1%
Other assets
32.4
34.8
19.9
-6.7%
Total assets
412
323
285
+27.7%
10-K for the year ended 31 December 2017, filed 27 February 2018: the filing.